Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.

Improvement in the medicinal chemistry of next-generation ADCs, their rational combination with ICIs and other agents, and the development of multiparametric immune biomarkers could help to significantly improve the outlook for patients with refractory aBC.